| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2020: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
To elucidate the role of increased SET expression in myofibroblasts in the cancer niche, and to provide the basis for anticancer strategies targeting cancer-related myofibroblasts (CAFs), I carried out this project.
As a result of investigating the effect of SET on myofibroblast phenotype and cancer tissue growth using the CAFs-like cell line LmcMF, Smad3 phosphorylation by the CAFs activator TGF-β was promoted by SET KD. It was clarified that the expression of OPG mRNA is suppressed by Smad3 inhibition and that the Smad promoter activity by TGF-β stimulation is promoted by SET KD.From the above, a part of the role of SET in the cancer niche has been clarified.
|
